GlassScriptPhysician profile
Katherine E Bertrand
NPI 1760980007
$4,498.03
in general payments reported to CMS, 2019-2025
36 companies · $2,539 in 2025
The $2,539 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $28.99 · 2023: $56.62 · 2024: $551 · 2025: $2,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,105.69 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.52 | 2021-2025 | |
| Novo Nordisk INC | $438.93 | 2021-2025 | Wegovy |
| Pfizer INC. | $427.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.58 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $313.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $302.78 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.78 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $155.02 | 2021-2025 | Trelegy Ellipta |
| Insulet Corporation | $140.33 | 2024-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $139.19 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $113.50 | 2021 | |
| Amgen INC. | $101.72 | 2021 | |
| Axsome Therapeutics, INC. | $98.91 | 2025 | Auvelity, Symbravo |
| Novartis Pharmaceuticals Corporation | $89.77 | 2025 | |
| Lundbeck LLC | $88.84 | 2025 | Rexulti |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Bertrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.